Analysis of Use of Antibacterial Drugs in 110 Discharged Patients with COVID-19

Objective To find out about the way antibacterial drugs were used in 110 discharged patients with COVID-19 in our hospital and to explore the rational use of antibacterial drugs in patients with COVID-19 Methods The data on 110 patients with COVID-19 who were discharged between January 24, 2020 and February 17, 2020 was collected, whose usage of antibacterial drugs, admission symptoms, results of chest CT examination and clinical classification, outcomes of etiological examination, and infection indicators were retrospectively analyzed Results Antibacterial drugs were used in all the 110 discharged patients, special-grade antibacterial drugs were used in 52 7% of them, and the percentage of patients who used a combination of antibacterial drugs was 78 2% The count of white blood cells was normal or somewhat low in most of these patients on admission, neutrophil counts were mostly in the normal range, and lymphocyte counts were mostly reduced to different extents During the detection after admission, 96 patients (87 3%) had normal procalcitonin (PCT) values, and 94 (85 5%) maintained normal PCT throughout the treatment Conclusion In the early stage of the COVID-19 outbreak, the combined use of broad-spectrum antibacterial drugs and the use of special grade antibacterial drugs were quite common With a better understanding of this disease later on, the use of antibacterial drugs was gradually standardized, while the cost and safety of antibacterial drugs were also taken into account